Medicines and vaccines for the world's poorest: Is there any prospect for public-private cooperation?

Globalization and Health

Volumn 1, Issue , 2005, Pages

  Scheffler, Richard M ^a,b   Pathania, Vikram ^b  

^a School of Public Health   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ATORVASTATIN; DIDANOSINE; EFAVIRENZ; GENERIC DRUG; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LAMIVUDINE; METFORMIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COOPERATION; DEVELOPING COUNTRY; DRUG COST; DRUG INDUSTRY; DRUG RESEARCH; HEALTH CARE ACCESS; HEALTH CARE NEED; HEALTH STATUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN RIGHTS; LIFE; PATENT; POVERTY; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW;

EID: 33746870513     PISSN: 17448603     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-8603-1-10     Document Type: Review

References (22)

1. For instance, 98% of the 10.5 million deaths among children under the age of 5 in 2002 were in developing countries. For details of the geographical distribution of the morbidity and mortality, see the World Health Report 2003 [http://www.who.int/whr/2003/en/Annex3-en.pdf].
2. Only 5% of those who require anti-retroviral therapy in the developing world have access to it. Less than 50,000 of 4 million AIDS patients in Sub-Saharan Africa are benefiting from ARV. See the World Health Report 2003 [http://www.who.int/whr/2003/en/overview_en.pdf].
3. [http://www.ims-global.com/globalinsights.htm].
4. Patented Medicine Review Board of Canada, Annual Report. 1999.
5. Economist. Trouble with Cheap Drugs. Jan 29, 2004
6. Ibid.
7. See the joint report by Drugs for Neglected Diseases and Medicins Sans Frontieres, "A Survey of Private Sector Drug Research and Development" [http://www.accessmed-msf.org/upload/ reportsandpublications/20920021753354/4-1.pdf]
8. Prusoff, William: "One Scientist's Story". The New York Times. March 19, 2001
9. Hunt, Michie: "Prescription Drugs and Intellectual Property Protection". National Institute for Health Care Management Issues Brief 2000 [http://www.nihcm.org/pharm.html].
10. [http://www.citizen.org/documents/Pharma_Report.pdf].
11. Scherer FM: "Pricing, Profits and Technological Progress in the Pharmaceutical Industry". The Journal of Economic Perspectives 1993, 7(3):97-115.
12. World Health Report. 2003.
13. Price data from PAHO [http://www.paho.org/English/HCP/HCA/ antiretrovirals_HP.htm]
14. Drug prices are computed from a NY Times report "Clinton Plan to Provide AIDS Drugs to Poor Countries'. October 23, 2003
15. See joint report by WHO/UNICEF/UNAIDS/MSF, "Sources and Prices of Selected Drugs and Diagnostics for People Living with HIV/AIDS". 2003.
16. For a good discussion of strategies to reduce prices see, "Surmounting Challenges: Procurement of Antiretroviral Medicines in Low- and Middle-Income Countries: The Experience of Medicins Sans Frontieres," a joint report by Access in Essential Medicines, WHO, and UNAIDS [http://www.who.int/medicines/library/par/]
17. Masaki E, et al.: "Cost-effectiveness of HIV Interventions for Resource Poor Countries: Setting Priorities for HIV/AIDS Management". [http://repositories.cdlib.org/big/hiv_prev/].
18. For a summary of industry concerns, see the FAQ [http://world.phrma.org]
19. Global Forum for Health Research, Initiative on Public-Private Partnerships for Health. 2003.
20. Wheeler, Craig, Berkley, Seth: "Initial lessons from public-private partnerships in drug and vaccine development". Bulletin of the World Health Organization 2001, 79(8):728-734.
21. [http://www.mmv.org].
22. [http://www.iavi.org].